Efficacy and safety of ziltivekimab in patients with chronic kidney disease susceptible to inflammatory diseases: a systematic review and meta-analysis of randomized controlled trials

• প্রধান লেখক: Amr Elrosasy (লেখক), Dalal Sabbagh (লেখক), Mohammad Assaf (লেখক), Husam Tarakhan (লেখক), Ahmad Afyouni (লেখক), Marwa O. Elgendy (লেখক), Lamiaa N. Abdelaty (লেখক), Refaat H. Omar (লেখক), Ahmed Hamdy Zabady (লেখক)
• বিন্যাস: গ্রন্থ
• প্রকাশিত: SpringerOpen, 2024-11-01T00:00:00Z.
• বিষয়গুলি: article
• অনলাইন ব্যবহার করুন: Connect to this object online.

Abstract Background Patients with chronic kidney disease (CKD) are at risk of developing conditions such as atherosclerosis and inflammation-induced anemia (AI) due to persistent inflammation. Ziltivekimab, an antibody targeting interleukin-6, is being studied for its potential to reduce inflammator...